Active, not recruitingNCT04127006
Rate of Progression in EYS Related Retinal Degeneration
Studying Retinitis pigmentosa
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Jaeb Center for Health Research
- Principal Investigator
- Mark Pennesi, MD, PhDRetina Foundation of the Southwest
- Enrollment
- 103 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2026
Study locations (19)
- University of California, San Francisco, San Francisco, California, United States
- Colorado Retina Associates, Denver, Colorado, United States
- Vitreo-Retinal Associates, Gainesville, Florida, United States
- University of Miami: Neuro-ophthalmology Department, Miami, Florida, United States
- Emory Eye Center, Atlanta, Georgia, United States
- Wilmer Eye Institute at Johns Hopkins, Baltimore, Maryland, United States
- Massachusetts Eye and Ear, Boston, Massachusetts, United States
- Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan, United States
- Duke University Eye Center, Durham, North Carolina, United States
- Oregon Health Science University Casey Eye Institute, Portland, Oregon, United States
- University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
- Retina Foundation of the Southwest, Dallas, Texas, United States
- University of Wisconsin-Madison: McPherson Eye Research Institute, Madison, Wisconsin, United States
- Hospital for Sick Children, Toronto, Canada
- Helsinki University Hospital, Helsinki, Finland
- +4 more locations on ClinicalTrials.gov
Collaborators
Foundation Fighting Blindness
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04127006 on ClinicalTrials.govOther trials for Retinitis pigmentosa
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07502664Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)Ray Therapeutics, Inc.
- RECRUITINGNANCT07266584Restoration of Central Vision With PRIMA in Patients With Photoreceptor DegenerationScience Corporation
- RECRUITINGNANCT07292987Implementation and Evaluation of a Post-Diagnostic Announcement Protocol at the CRMR RefeRet, Quinze-Vingts HospitalCentre Hospitalier National d'Ophtalmologie des Quinze-Vingts
- RECRUITINGNCT07228793Natural History Study of Patients With EYS-Associated RPSensor Technology for Deafblind
- RECRUITINGPHASE1, PHASE2NCT06891885A Study to Investigate the Safety of DSP-3077 After a Unilateral Eye Injection in Male and Female Participants 18 Years of Age or Older With Retinitis PigmentosaSumitomo Pharma America, Inc.
- RECRUITINGPHASE2NCT07174726A Phase 2 Open-label Study to Evaluate the Safety of Laruparetigene Zovaparvovec Administered Bilaterally in Male Participants With X-Linked Retinitis PigmentosaBeacon Therapeutics
- RECRUITINGPHASE2NCT06628947A Phase II Study of Intravitreal KIO-301 in Patients With Late-stage Retinitis PigmentosaKiora Pharmaceuticals, Inc.
- RECRUITINGPHASE2NCT06912633Safety of a Single, Intravitreal Injection of 6.0M jCell (Famzeretcel) in Retinitis Pigmentosa (RP)jCyte, Inc